Boston Scientific Corp.
Boston Scientific (BSX) is a global medical‑devices company with a market capitalisation of about $148.03bn, selling products used in cardiology, rhythm management, peripheral interventions, endoscopy and urology. Investors should know it earns recurring revenue from disposable devices and procedure-driven demand, backed by ongoing R&D and product launches. The business benefits from demographic trends such as an ageing population and wider access to minimally invasive therapies, yet it faces stiff competition from large peers, reimbursement and regulatory pressures, and occasional product or legal setbacks. Financial performance can be influenced by procedure volumes, hospital capital spending, foreign exchange and the success of new technologies. For investors, Boston Scientific offers exposure to healthcare innovation but also to sector-specific operational and regulatory risks. This is general educational information, not personalised advice — values can rise and fall and past performance is not a reliable guide to future returns.
Why It's Moving
Analysts Slash BSX Targets on Tepid 2026 Outlook, Yet See Bullish Long-Term Momentum.
- RBC Capital cut its target to $115 from $130 post-earnings, highlighting multiple growth catalysts like electrophysiology despite the stock's 18% plunge.
- Q4 sales and EPS topped estimates, with Urology up 3.2% to $717M and Neuromodulation surging 9.9% to $332M on new launches, signaling strong product demand.
- Consensus holds at Strong Buy with medians around $100-$130, implying hefty upside as margins eye 28.7% and revenue growth hits 13.8%.
Analysts Slash BSX Targets on Tepid 2026 Outlook, Yet See Bullish Long-Term Momentum.
- RBC Capital cut its target to $115 from $130 post-earnings, highlighting multiple growth catalysts like electrophysiology despite the stock's 18% plunge.
- Q4 sales and EPS topped estimates, with Urology up 3.2% to $717M and Neuromodulation surging 9.9% to $332M on new launches, signaling strong product demand.
- Consensus holds at Strong Buy with medians around $100-$130, implying hefty upside as margins eye 28.7% and revenue growth hits 13.8%.
When is the next earnings date for Boston Scientific Corp. (BSX)?
Boston Scientific's next earnings date is estimated for April 22, 2026, ahead of the market open, though some sources indicate a range through late April. This report will cover the first quarter of 2026 (Q1 2026). Investors should monitor official company announcements for confirmation, as dates align with historical late-April patterns for Q1 releases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Boston Scientific stock, anticipating a significant increase in its value.
Financial Health
Boston Scientific is performing well with strong revenue and cash flow, indicating solid overall financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BSX
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketStagflation Standouts
This collection features stocks and assets carefully selected by professional analysts to potentially outperform during stagflation periods. These defensive investments have already shown strength while the broader market struggles, making them worth consideration for economic uncertainty ahead.
Published: May 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Procedure demand tailwind
An ageing population and rising access to minimally invasive procedures can support long‑term demand, though volumes can ebb with hospital spending cycles.
Innovation and R&D
Regular product launches and technological improvements drive share gains and pricing power, but new products must clear regulatory and commercial hurdles.
Regulatory and market risks
Exposure to reimbursement, recalls and litigation means performance can be volatile; investors should weigh potential returns against these sector‑specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
